Technical Data
24 Dec 2024

Biointron Insights: Antibody Industry Report (Q3 2024 Insights, Trends & Analysis)

This report aims to explore the events and trends of the biopharmaceutical industry in Q3 (July, August, September).
https://www.biointron.com/industry-trends/biointron-insights-antibody-industry-report-q3-2024-insights-trends-analysis.html

This quarter saw an increase in research trends in higher drug–antibody ratios for antibody-drug conjugates (ADCs), with promising approaches to address the problem of high hydrophobicity. Positive results in various clinical trials for anti-TIGIT therapies have also excited the field, with safety and pharmacovigilance at the center after numerous failures. Here, we give an example of a promising monoclonal antibody in development.

To learn more, download the trends report here: https://www.biointron.com/industry-trends/biointron-insights-antibody-industry-report-q3-2024-insights-trends-analysis.html

Content provided by our supplier

Biointron Biological

  • US
  • 2024
    On CPHI since
  • 2
    Certificates
  • 500 - 999
    Employees
Company types
Contract Research Organisation (CRO)
Primary activities
Contract Research Organisation

Other Content from Biointron Biological (2)